Cargando…

Comprehensive Landscape of Heparin Therapy for COVID-19

The pandemic coronavirus disease 2019 (COVID-19), caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading globally. Clinical observations found that systemic symptoms caused by SARS-CoV-2 infection are attenuated when using the anticoagulant agen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Chen, Tingting, Wu, Li, Jin-Ping, Sullivan, Mitchell A., Wang, Cong, Wang, Hanxiang, Deng, Bin, Zhang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581413/ https://www.ncbi.nlm.nih.gov/pubmed/33357843 http://dx.doi.org/10.1016/j.carbpol.2020.117232

Ejemplares similares

The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study
por: Shi, Chen, et al.
Publicado: (2020)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases
por: Kondashevskaya, M. V.
Publicado: (2022)

Surviving Covid-19 with Heparin?
por: ten Cate, Hugo
Publicado: (2021)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing
por: Jiang, Lan, et al.
Publicado: (2022)

Heparin-Induced Thrombocytopenia in COVID-19
por: Lingamaneni, Prasanth, et al.
Publicado: (2020)

Heparin-induced thrombocytopenia and COVID-19
por: Sartori, Michelangelo, et al.
Publicado: (2021)

Heparin in Penicillin Therapy
por: Martin, Peter
Publicado: (1945)

Heparin Therapy Improving Hypoxia in COVID-19 Patients – A Case Series
por: Negri, Elnara Marcia, et al.
Publicado: (2020)

Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy
por: Liao, Li, et al.
Publicado: (2017)

Heparin-induced thrombocytopenia among patients of a comprehensive cancer center
por: Wu, Weixin, et al.
Publicado: (2014)

The trans-omics landscape of COVID-19
por: Wu, Peng, et al.
Publicado: (2021)

Heparin-Induced Thrombocytopenia in Severe COVID-19
por: Daviet, Florence, et al.
Publicado: (2020)

Heparin Induced Thrombocytopenia in Patients with COVID-19
por: Warrior, Surbhi, et al.
Publicado: (2020)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Potential value of heparin in COVID-19 related cardiovascular disease
por: Yu, Xianqiang
Publicado: (2021)

The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
por: Reichman-Warmusz, Edyta, et al.
Publicado: (2022)

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Comprehensive analysis of ferritinophagy-related genes and immune infiltration landscape in diabetic retinopathy
por: Yu, Fenfen, et al.
Publicado: (2023)

Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma
por: Zhang, Ze, et al.
Publicado: (2023)

Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica
por: Liu, Zhu, et al.
Publicado: (2022)

Characterizing Heparin Tetrasaccharides Binding to Amyloid-Beta Peptide
por: Zhou, Xiang, et al.
Publicado: (2022)

Evaluating the immunogenicity of heparin and heparin derivatives by measuring their binding to platelet factor 4 using biolayer interferometry
por: Chen, Qingqing, et al.
Publicado: (2022)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Nebulized Heparin for Post-COVID-19-Related Hypoxia
por: Hursitoglu, Mehmet, et al.
Publicado: (2021)

Spontaneous Heparin-Induced Thrombocytopenia and COVID-19 Infection
por: Amara, Suneetha
Publicado: (2021)

Non-anticoagulant heparin derivatives for COVID-19 treatment
por: Cao, Min, et al.
Publicado: (2023)

Comprehensive analysis of the chromatin landscape in Drosophila
por: Kharchenko, Peter V., et al.
Publicado: (2010)

Heparin and Derivatives for Advanced Cell Therapies
por: Laner-Plamberger, Sandra, et al.
Publicado: (2021)

Correction: Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica
por: Liu, Zhu, et al.
Publicado: (2023)

Lipid-mRNA nanoparticles landscape for cancer therapy
por: Li, Yin, et al.
Publicado: (2022)

Use of low molecular weight heparin and hemoglobin fall in COVID-19 patients: A STROBE-compliant study
por: Hong, Ping-Yang, et al.
Publicado: (2022)

Global analysis of the COVID-19 research landscape and scientific impact
por: Chen, Ying, et al.
Publicado: (2022)

DRESIS: the first comprehensive landscape of drug resistance information
por: Sun, Xiuna, et al.
Publicado: (2022)

The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
por: May, Jori E., et al.
Publicado: (2020)

Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
por: Costanzo, Luca, et al.
Publicado: (2020)

Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vr7mvr7vhqa9072kabmkhsbf3s